Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in ...

Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, ...

Tech and cancer researchers are publicly releasing an AI tool that can perform sophisticated tumor analysis in a fraction of the time and cost of existing methods.

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with ...

“The research that’s needed most is the risk stratification research—who do we screen,” says Dr. Gabre. By getting to the ...

The complete response or better rate was 81.1% with the combination versus 31.1% in the control arm, while patients treated ...

Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investi ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line[1] Data ...